Clinical Trials on Recurrent Hepatocellular Carcinoma

Total 27975 results

Cancer Institute and Hospital, Chinese Academy...

Recruiting

TQB2450 Combined With Anlotinib Hydrochloride in the Perioperative Treatment of Hepatocellular Carcinoma Hydrochloride Neoadjuvant Therapy for Resectable Hepatocellular Carcinoma With a High Risk of Recurrence or Metastasis

Patients With Resectable Hepatocellular Carcinoma Who Are at High Risk of Recurrence or Metastasi

China
Chiayi Christian Hospital
National Taiwan University Hospital; Mackay Memorial Hospital; National Cheng-Kung... and other collaborators

Recruiting

Statin for Preventing Hepatocellular Carcinoma Recurrence After Curative Treatment (SHOT)

HepatoCellular Carcinoma

Taiwan
Eastern Hepatobiliary Surgery Hospital
Sun Yat-sen University; Shanghai Zhongshan Hospital; First Affiliated Hospital... and other collaborators

Unknown

Effect of Babaodan on Tumor Recurrence After Curative Resection of Hepatocellular Carcinoma

Hepatocellular Carcinoma | Tumor Recurrence
Zhujiang Hospital

Recruiting

Prediction of Hepatocellular Carcinoma Recurrence After Curative Treatment by Longitudinal Monitoring MRD Based on ctDNA

Hepatocellular Carcinoma Resectable

China
Chinese PLA General Hospital
Immunotech Applied Science Ltd.

Recruiting

Expanded Activated Lymphocytes (EAL) as Adjuvant Therapy in Patients With HCC at High Risk of Recurrence After Radical Resection

Hepatocellular Carcinoma (HCC)

China
All India Institute of Medical Sciences, New Delhi

Unknown

Effectiveness of Chemotherapy in Metastatic or Recurrent Carcinoma Cervix

Metastatic Carcinoma to the Uterine Cervix | Recurrent Carcinoma Cervix | Cervix Carcinoma Recurrent

India
ECOG-ACRIN Cancer Research Group
National Cancer Institute (NCI)

Completed

Implementing a Virtual Tobacco Treatment for Cancer Patients in Community Oncology Practices

Current Smoker | Malignant Neoplasm | Carcinoma In Situ | Primary Neoplasm | Recurrent Neoplasm

United States
Chang Gung Memorial Hospital

Completed

Oral Thalidomide and Tegafur-uracil to Decrease Hepatocellular Carcinoma Recurrence

Adult Hepatocellular Carcinoma | Recurrent Hepatocellular Carcinoma | Adverse Reaction to Drug | Vascular Endothelial Growth Factor Overexpression

Taiwan
National Cancer Institute (NCI)

Completed

Erlotinib in Treating Patients With Unresectable Liver, Bile Duct, or Gallbladder Cancer

Advanced Adult Primary Liver Cancer | Localized Unresectable Adult Primary Liver Cancer | Recurrent Adult Primary Liver Cancer | Recurrent Extrahepatic Bile Duct Cancer | Recurrent Gallbladder Cancer | Unresectable Extrahepatic Bile Duct Cancer | Unresectable Gallbladder Cancer | Adult Primary Hepatocellular... and other conditions

United States
Zhujiang Hospital

Not yet recruiting

Compare the Accuracy of ctDNA-MRD and MVI Result in Predicting Postoperative Recurrence of Hepatocellular Carcinoma

Recurrence | Surgery | Hepatocellular Carcinoma Resectable

China
Anhui Medical University
National Natural Science Foundation of China

Completed

Impact of Hepatectomy on HCC Recurrence (HCC)

Recurrence | Hepatocellular Carcinoma Stage I

China
Jiangsu HengRui Medicine Co., Ltd.

Active, not recruiting

A Study to Evaluate Camrelizumab Plus Rivoceranib (Apatinib) as Adjuvant Therapy in Patients With Hepatocellular Carcinoma (HCC) at High Risk of Recurrence After Curative Resection or Ablation

Hepatocellular Carcinoma (HCC)

China
Center Eugene Marquis
Rennes University Hospital

Completed

188RE-SSS Lipiodol to Treat HepatoCellular Carcinomas (LIP-RE-I)

Hepatocellular Carcinomas

France
Jiangsu HengRui Medicine Co., Ltd.

Active, not recruiting

A Study to Evaluate Camrelizumab Plus Rivoceranib (Apatinib) Versus Camrelizumab as Adjuvant Therapy in Patients With Hepatocellular Carcinoma (HCC) at High Risk of Recurrence After Curative Resection or Ablation

Adjuvant Therapy in Patients With Hepatocellular Carcinoma (HCC) at High Risk of Recurrence After Curative Resection or Ablation

China
Chang Gung Memorial Hospital
Ministry of Health and Welfare, Taiwan

Recruiting

Innovative Diagnosis and Therapy in LDLT Patients With High-risk Hepatocellular Carcinoma

High Risk of Recurrence

Taiwan
University of Milano Bicocca
Humanitas Clinical and Research Center; Niguarda Hospital; Azienda Ospedaliero... and other collaborators

Recruiting

The Role Of Circulating Tumor Cells As Markers Of Advanced Disease And Prognosis In HCC

Hepatocellular Carcinoma | Circulating Tumor Cell | Recurrent Hepatocellular Carcinoma

Italy
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Recruiting

Stereotactic Body Radiation Therapy or Intensity Modulated Radiation/Proton Therapy in Treating Patients With Recurrent Head and Neck Cancer

Recurrent Head and Neck Carcinoma

United States
Academic and Community Cancer Research United
National Cancer Institute (NCI)

Recruiting

A Phase II Study of Nivolumab + Ipilimumab in Advanced HCC Patients Who Have Progressed on First Line Atezolizumab + Bevacizumab

Unresectable Hepatocellular Carcinoma | Stage III Hepatocellular Carcinoma AJCC v8 | Stage IIIA Hepatocellular Carcinoma AJCC v8 | Stage IV Hepatocellular Carcinoma AJCC v8 | Stage IVA Hepatocellular Carcinoma AJCC v8 | Stage IVB Hepatocellular Carcinoma AJCC v8 | BCLC Stage B Hepatocellular Carcinoma and other conditions

United States
Roswell Park Cancer Institute
National Comprehensive Cancer Network

Completed

Sorafenib Tosylate in Treating Patients With Liver Cancer That Cannot Be Removed by Surgery

Advanced Adult Hepatocellular Carcinoma | Localized Non-Resectable Adult Hepatocellular Carcinoma | Stage IIIA Hepatocellular Carcinoma | Stage IIIB Hepatocellular Carcinoma | Stage IIIC Hepatocellular Carcinoma | Stage IVA Hepatocellular Carcinoma | Stage IVB Hepatocellular Carcinoma | Stage III... and other conditions

United States
Roswell Park Cancer Institute
Merck Sharp & Dohme LLC

Active, not recruiting

Sorafenib Tosylate and Pembrolizumab in Treating Patients With Advanced or Metastatic Liver Cancer

Advanced Adult Hepatocellular Carcinoma | Child-Pugh Class A | Stage III Hepatocellular Carcinoma | Stage IIIA Hepatocellular Carcinoma | Stage IIIB Hepatocellular Carcinoma | Stage IIIC Hepatocellular Carcinoma | Stage IV Hepatocellular Carcinoma | Stage IVA Hepatocellular Carcinoma | Stage IVB Hepatocellular...

United States
Ain Shams University

Completed

Single Center Experience Over a Decade in Living Donor Liver Transplantation for Egyptian Patients With Hepatocellular Carcinoma: Stretching the Limits

Recurrence of HCC After LDLT

Egypt
National Cancer Institute (NCI)

Terminated

Dasatinib in Treating Patients With Advanced Liver Cancer That Cannot Be Removed by Surgery

Advanced Adult Primary Liver Cancer | Recurrent Adult Primary Liver Cancer | Adult Primary Hepatocellular Carcinoma

United States
Assistance Publique - Hôpitaux de Paris

Completed

Multipolar Radiofrequency Ablation for Hepatocellular Carcinoma Using Extra Nodular Versus Intranodular Technique (ARMCENVIN)

Hepatocellular Carcinomas

France
Radiation Therapy Oncology Group
National Cancer Institute (NCI); NRG Oncology

Active, not recruiting

Sorafenib Tosylate With or Without Stereotactic Body Radiation Therapy in Treating Patients With Liver Cancer

Advanced Adult Primary Liver Cancer | Recurrent Adult Primary Liver Cancer | Adult Primary Hepatocellular Carcinoma

United States, Canada, Australia, Hong Kong, Korea, Republic of
Academic and Community Cancer Research United
National Cancer Institute (NCI); Genentech, Inc.

Recruiting

Atezolizumab in Combination With a Multi-Kinase Inhibitor for the Treatment of Unresectable, Locally Advanced, or Metastatic Liver Cancer

Unresectable Hepatocellular Carcinoma | Stage III Hepatocellular Carcinoma AJCC v8 | Stage IIIA Hepatocellular Carcinoma AJCC v8 | Stage IV Hepatocellular Carcinoma AJCC v8 | Stage IVA Hepatocellular Carcinoma AJCC v8 | Stage IVB Hepatocellular Carcinoma AJCC v8 | Stage IIIB Hepatocellular Carcinoma... and other conditions

United States
City of Hope Medical Center
National Cancer Institute (NCI)

Recruiting

Durvalumab and Tremelimumab After Radioembolization for the Treatment of Unresectable, Locally Advanced Liver Cancer

Unresectable Hepatocellular Carcinoma | Stage III Hepatocellular Carcinoma AJCC v8 | Stage IIIA Hepatocellular Carcinoma AJCC v8 | Stage IV Hepatocellular Carcinoma AJCC v8 | Stage IVA Hepatocellular Carcinoma AJCC v8 | Stage IVB Hepatocellular Carcinoma AJCC v8 | BCLC Stage B Hepatocellular Carcinoma and other conditions

United States
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Active, not recruiting

Phase Ib Study of Erlotinib Prior to Surgery in Patients With Head and Neck Cancer

Recurrent Head and Neck Carcinoma | Recurrent Skin Carcinoma | Recurrent Salivary Gland Carcinoma | Skin Squamous Cell Carcinoma

United States
National Cancer Institute (NCI)

Terminated

BMS-247550 in Treating Patients With Liver or Gallbladder Cancer

Advanced Adult Primary Liver Cancer | Localized Extrahepatic Bile Duct Cancer | Localized Gallbladder Cancer | Localized Resectable Adult Primary Liver Cancer | Localized Unresectable Adult Primary Liver Cancer | Recurrent Adult Primary Liver Cancer | Recurrent Extrahepatic Bile Duct Cancer | Recurrent... and other conditions

United States
Roswell Park Cancer Institute
National Cancer Institute (NCI)

Active, not recruiting

Genetically Modified T Cells and Decitabine in Treating Patients With Recurrent or Refractory Ovarian, Primary Peritoneal, or Fallopian Tube Cancer

Recurrent Fallopian Tube Carcinoma | Recurrent Ovarian Carcinoma | Recurrent Primary Peritoneal Carcinoma

United States
Gynecologic Oncology Group
National Cancer Institute (NCI)

Completed

Dalantercept in Treating Patients With Recurrent Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cavity Cancer

Recurrent Fallopian Tube Carcinoma | Recurrent Ovarian Carcinoma | Recurrent Primary Peritoneal Carcinoma

United States
National Cancer Institute (NCI)

Completed

Cabozantinib or Paclitaxel in Treating Patients With Persistent or Recurrent Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cavity Cancer

Recurrent Fallopian Tube Carcinoma | Recurrent Ovarian Carcinoma | Recurrent Primary Peritoneal Carcinoma

United States
National Cancer Institute (NCI)
NRG Oncology

Completed

Bevacizumab With or Without Fosbretabulin Tromethamine in Treating Patients With Recurrent or Persistent Ovarian Epithelial, Fallopian Tube, or Peritoneal Cavity Cancer

Recurrent Fallopian Tube Carcinoma | Recurrent Ovarian Carcinoma | Recurrent Primary Peritoneal Carcinoma

United States
Tata Memorial Hospital

Unknown

Tomotherapy in Postsurgery Recurrent Carcinoma Cervix

Postsurgery Recurrent Carcinoma Cervix

India
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Recruiting

Adavosertib With or Without Olaparib in Treating Patients With Recurrent Ovarian, Primary Peritoneal, or Fallopian Tube Cancer

Recurrent Fallopian Tube Carcinoma | Recurrent Ovarian Carcinoma | Recurrent Primary Peritoneal Carcinoma

United States
Northwestern University
National Cancer Institute (NCI); Merck Sharp & Dohme LLC; Astex Pharmaceuticals...

Completed

Guadecitabine and Pembrolizumab in Treating Patients With Recurrent Ovarian, Primary Peritoneal, or Fallopian Tube Cancer

Recurrent Fallopian Tube Carcinoma | Recurrent Ovarian Carcinoma | Recurrent Primary Peritoneal Carcinoma

United States
ECOG-ACRIN Cancer Research Group
National Cancer Institute (NCI)

Terminated

Perfusion CT in Predicting Outcomes in Ovarian, Fallopian, or Peritoneal Cancer With Bevacizumab

Recurrent Fallopian Tube Carcinoma | Recurrent Ovarian Carcinoma | Recurrent Primary Peritoneal Carcinoma

United States
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Withdrawn

PD 0360324 and Cyclophosphamide in Treating Patients With Recurrent High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer

Recurrent Fallopian Tube Carcinoma | Recurrent Ovarian Carcinoma | Recurrent Primary Peritoneal Carcinoma

United States
Gynecologic Oncology Group
National Cancer Institute (NCI)

Completed

Rilotumumab in Treating Patients With Persistent or Recurrent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer

Recurrent Fallopian Tube Carcinoma | Recurrent Ovarian Carcinoma | Recurrent Primary Peritoneal Carcinoma

United States
Gynecologic Oncology Group
National Cancer Institute (NCI)

Completed

A Phase II Evaluation of Dasatinib (Sprycel®, NSC #732517) in the Treatment of Persistent or Recurrent Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Carcinoma

Recurrent Fallopian Tube Carcinoma | Recurrent Ovarian Carcinoma | Recurrent Primary Peritoneal Carcinoma

United States
Sun Yat-sen University

Recruiting

A RCT of TNF and ENT in the Treatment of Long-term Prognosis With Hepatitis B-related HCC After Curative Resection

Hepatocellular Carcinoma Recurrent

China
National Cancer Institute (NCI)

Completed

Bevacizumab in Treating Patients With Unresectable Nonmetastatic Liver Cancer

Localized Unresectable Adult Primary Liver Cancer | Recurrent Adult Primary Liver Cancer | Adult Primary Hepatocellular Carcinoma

United States
Mayo Clinic
National Cancer Institute (NCI)

Recruiting

Futibatinib and Pembrolizumab for Treatment of Advanced or Metastatic FGF19 Positive BCLC Stage A, B, or C Liver Cancer

Advanced Hepatocellular Carcinoma | BCLC Stage B Hepatocellular Carcinoma | BCLC Stage C Hepatocellular Carcinoma | Metastatic Hepatocellular Carcinoma | BCLC Stage A Hepatocellular Carcinoma

United States
Northwestern University
Bristol-Myers Squibb; National Cancer Institute (NCI)

Completed

Nivolumab and Yttrium Y 90 Glass Microspheres in Treating Patients With Advanced Liver Cancer

Stage IIIA Hepatocellular Carcinoma | Stage IIIB Hepatocellular Carcinoma | Stage IIIC Hepatocellular Carcinoma | Stage IVA Hepatocellular Carcinoma | Stage IVB Hepatocellular Carcinoma

United States
National Cancer Institute (NCI)

Completed

Tremelimumab With Chemoembolization or Ablation for Liver Cancer

Hepatocellular Carcinoma | Biliary Tract Neoplasms | Liver Cancer | Biliary Cancer | Heptocellular Cancer

United States
National Cancer Institute (NCI)
Gynecologic Oncology Group

Completed

Gefitinib in Treating Patients With Persistent or Recurrent Endometrial Cancer

Recurrent Uterine Corpus Carcinoma

United States
University of Washington
National Cancer Institute (NCI); United States Department of Defense

Recruiting

Pembrolizumab and Carboplatin for the Treatment of Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Recurrent Fallopian Tube Carcinoma | Recurrent Ovarian Carcinoma | Recurrent Primary Peritoneal Carcinoma

United States
University of Washington
National Cancer Institute (NCI); Merck Sharp & Dohme LLC

Completed

Pembrolizumab and Carboplatin in Treating Patients With Relapsed or Refractory Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Recurrent Fallopian Tube Carcinoma | Recurrent Ovarian Carcinoma | Recurrent Primary Peritoneal Carcinoma

United States
GOG Foundation
National Cancer Institute (NCI)

Completed

Bevacizumab With or Without Everolimus in Treating Patients With Recurrent or Persistent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer

Recurrent Fallopian Tube Carcinoma | Recurrent Ovarian Carcinoma | Recurrent Primary Peritoneal Carcinoma

United States
National Cancer Institute (NCI)
NRG Oncology

Completed

Paclitaxel With or Without Viral Therapy in Treating Patients With Recurrent or Persistent Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cancer

Recurrent Fallopian Tube Carcinoma | Recurrent Ovarian Carcinoma | Recurrent Primary Peritoneal Carcinoma

United States
National Cancer Institute (NCI)
NRG Oncology

Completed

Paclitaxel With or Without Pazopanib Hydrochloride in Treating Patients With Persistent or Recurrent Ovarian Epithelial, Fallopian Tube, or Peritoneal Cavity Cancer

Recurrent Fallopian Tube Carcinoma | Recurrent Ovarian Carcinoma | Recurrent Primary Peritoneal Carcinoma

United States

Clinical Trials on Recurrent Hepatocellular Carcinoma

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Switzerland

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations